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Abstract
Background: The current treatment results of laryngeal squamous cell carcinoma still
remain modest. Various prognostic factors have been investigated and need to be
included in the management decision making.
Methods: We reviewed the pertinent literature regarding host, tumor, and treatment
factors as prognostic indicators that influence outcome in patients diagnosed with
laryngeal squamous cell carcinoma.
Results: Host, tumor, and treatment factors all have an important impact upon an
individual patient's prognosis with laryngeal squamous cell carcinoma, whereas stag-
ing systems only take into account tumor factors. There is much work yet to be done
to establish reliable, independent biomarkers that predict survival and response to
treatment.
Conclusions: Optimal outcomes for an individual patient can be achieved when tak-
ing into account tumor, host, and treatment factors.
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1 | INTRODUCTION
The current treatment results of laryngeal squamous cell carcinoma still
remain modest with global 5-year overall incidence rates of 154 977
male cases and 22 445 female cases in 2018.1 In 2018, there were
81 806 male deaths and 12 965 female deaths worldwide from larynx
cancer. The 5-year relative survival rate for all stages of larynx cancer
varies widely according to tumor site and stage. Various factors predict
the outcome of malignant neoplasms of the larynx. These can be
grouped into host, tumor, and treatment. Host factors include age,
gender, nutritional status, physical and psychological performance sta-
tus, comorbidities, and immunological response. Tumor factors include
tumor site, TNM stage, grade, and the presence of a second primary
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cancer (synchronous or metachronous). Treatment factors include all
available approaches to therapy and various combinations of these
modalities in addition to location of treatment, that is, academic or
research/teaching hospitals vs community hospitals. We reviewed the
pertinent literature regarding host, tumor, and treatment factors as
prognostic indicators that influence survival outcome in patients diag-
nosed with laryngeal squamous cell carcinoma. Host, tumor, and treat-
ment factors all have an important impact upon an individual patient's
prognosis with laryngeal squamous cell carcinoma, whereas current
staging systems only take into account tumor factors.
2 | HOST FACTORS
2.1 | Age
Data in the literature are controversial concerning the effects of age
on survival. Some authors state that the prognosis is better in younger
patients, whereas others report it being better in the elderly. In the
general head and neck cancer population, younger age has been con-
sidered as a positive prognostic factor. In a series of 1030 head and
neck cancer patients, Lacy et al found that younger patients had a sig-
nificantly better five-year survival rate than middle-aged or old
patients.2 Age remained a significant factor even after controlling for
smoking, comorbidity, primary site, TNM stage, and nodal disease.
Young patients also developed fewer recurrences and second primary
tumors. In the population-based study by Misono et al comprising
10 429 patients in the Surveillance, Epidemiology, and End Results
(SEER) database, better survival was observed with younger age.3
Conversely, in a smaller Norwegian series of 1616 laryngeal squamous
cell carcinoma (LSCC) patients, an increased risk for a recurrence was
observed in patients who were younger than 70 years.4
2.2 | Gender
The site of laryngeal carcinoma differs widely according to gender.
Women are more likely to have cancer of the supraglottis than of the
glottis. In a review, the ratio of glottic to supraglottic tumors was
2.12:1 in men and 0.56:1 in women, which remains highly significant.5
In a multicenter study comprising 4005 patients with head and neck
cancer, women with laryngeal cancer had a reduced risk for recur-
rence compared with men (HR = 0.39, 95% CI: 0.24-0.74).6 In a series
of 1252 consecutive patients with LSCC who all were treated with
primary radiotherapy, multivariate analyses revealed that male gender
was a significant factor in predicting locoregional failure, death from
cancer, and death from all causes.7
2.3 | Nutritional status
Malnutrition is a common problem among patients with advanced
laryngeal cancer. In a retrospective study by Li et al of 473 patients
with LSCC, low BMI before treatment was significantly associated
with poor overall survival as an independent poor prognostic factor
(P < .001).8 This correlates closely with the host's immunocompe-
tence. Patients in negative nitrogen balance have a poorer general
condition and respond less well to therapy.9 In particular patients with
weight loss of more than 10% during the 6 months before surgery are
a great risk for the occurrence of major postoperative complications.10
Clearly, there are challenges with optimizing nutrition in patients diag-
nosed with larynx cancer and undergoing treatment. Malnourished
patients should be supported with pre-treatment tube feeding nutri-
tional support.11 Drawing upon literature from other patient cohorts,
there is evidence that high carbohydrate supplements preoperatively
improve outcome in colorectal surgery.12
2.4 | Performance status
World Health Organization (WHO) performance status for each
patient is an important factor to be included in the decision making
when the type of individual LSCC treatment is considered (Table 1). In
addition to smoking and drinking being prevalent among LSCC
patients and affecting their performance status also comorbidities
have an impact. Bøje et al studied the impact of comorbidity on treat-
ment outcome in a series of 12 623 Danish head and neck cancer
patients and found that 36% of them were affected by comorbidity at
the time of diagnosis.13 Poor general condition has been related to
the risk of recurrences14,15 and it naturally deteriorates with increas-
ing age.16 Anemia has been recognized as a factor contributing to
decreased locoregional control after definitive RT for T1-T2N0 glottic
LSCC.17 This was supported by the study by Johansen et al in a series
of 1252 Danish LSCC patients treated with primary radiotherapy.7
Hemoglobin was found to be an independent prognostic factor. The
host's general condition is usually evaluated according to different
systems. Some of them are also used in oncology to measure the qual-
ity of life of cancer patients, as for example the Performance Status
Scale for Head and Neck Cancer Patients,18 the Spitzer Quality of Life
TABLE 1 WHO performance status
Grade Explanation of activity
0 Fully active, able to carry on all pre-disease performance
without restriction
1 Restricted in physically strenuous activity but ambulatory
and able to carry out work of a light or sedentary nature,
for example, light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry
out any work activities. Up and about more than 50% of
waking hours
3 Capable of only limited selfcare, confined to bed or chair
more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally
confined to bed or chair
5 Dead
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Index,19 the Functional Assessment of Cancer Therapy-Head and
Neck Version,20 and the Charlson Comorbidity Index.21,22
List et al suggest the use of the Functional Assessment of Cancer
Therapy—Head and Neck Scale and the Performance Status for Head
and Neck Cancer Patients to describe performance status and quality
of life of head and neck cancer patients.23 The patient's performance
status can affect not only prognosis but also the choice of treat-
ment.24 Patients with decreased functional capacity may be deemed
“too sick” for one treatment (eg, surgery) and thus receive an alterna-
tive (eg, radiotherapy).24 Patients with cancer of the larynx often have
other diseases and illnesses in addition to their cancer. These other
conditions, which are generally referred to as comorbidities25 have a
profound effect on treatment selection and prognosis.26
Piccirillo and Feinstein24 have emphasized that the American
Joint Committee on Cancer (AJCC) TNM system for cancer staging is
old and is constrained in its ability to provide useful prognostic infor-
mation. Tumor descriptive data are conserved to four disease
“stages,” which are associated with a statistical gradient, but this stag-
ing process is very limited in terms of predictive utility. Information
beyond the gross and microscopic extent of the cancer is needed to
recommend optimal and individualized treatment regimens and to
answer questions raised by our patients.
As our knowledge of tumor biology and molecular markers
increases, we will be able to expand the number of significant variables
available to predict tumor behavior, host resistance, and the probability
of a successful outcome. The presence of comorbidity influences treat-
ment selection and subsequent outcome.13 Chemoradiotherapy is used
less often in patients older than 70 years of age and in those with
comorbidity.27 Having a comorbidity was associated with higher rates
of postoperative complications.28 However, having a comorbidity does
not impact the effectiveness of radiation therapy.29 A meta-analysis
was performed using comorbidity as a prognostic factor showed that
overall survival was significantly poorer for patients with comorbidity.29
2.5 | Immunological response
The cellular immunologic function of laryngeal cancer patients is lower
than that of healthy persons and the function of late-staged patients is
lower than that of the early-staged patients.30Many patientswith cancer
of the larynx have immune deficits or abnormal immune reactions but
this altered immunologic condition could depend on multiple mecha-
nisms (alcohol abuse, viruses, malnutrition, aging, etc.). There are data to
support adverse prognostic impactwith immunosuppressed patients.31
3 | TUMOR FACTORS
3.1 | Site
The Surveillance, Epidemiology, and End Results (SEER) database
tracks relative 5-year survival rates for larynx cancer in the United
States. Five-year relative survival rates for patients with larynx cancer
varies according to primary tumor site. Based upon data from SEER
2009-2015, 60.3% of patients diagnosed with laryngeal cancer sur-
vive 5 years.32 The 5-year relative survival rates for localized laryngeal
cancer is 77.4%, with regional involvement, the survival decreases to
44.7% at 5 years, and only 33.3% of patients with distant disease sur-
vive 5 years.32 The 5-year relative survival rates for supraglottic can-
cers, according to the SEER database, is 46%. Glottic cancers have the
best 5-year relative survival rate, 77%, due to a higher percentage of
patients presenting with localized disease (83%). Patients with sub-
glottic primary tumors have a 5-year relative survival rate of 53%.32
Further, supraglottic primary tumors more often recur when com-
pared with those with glottic primary tumors.4,7 Supraglottic tumors
are known to have higher rates of regional nodal metastasis, whereas
the glottic site is a relative watershed area for lymphatic spread.
3.2 | T class
When the International Union Against Cancer published the docu-
ment TNM Classification of Malignant Tumours in 198733 and the
American Joint Committee on Cancer followed with the same system
in 198834 there was agreement for the first time on the TNM classifi-
cation for laryngeal cancer. It is important to recognize that the TNM
laryngeal cancer classification provides a standardized group of cate-
gories for patients with laryngeal cancer, which is to say that the sys-
tem allows us to stratify patients according to the stage of their
disease at presentation.35 We may thus share clinical observations
from different parts of the world, confident in the knowledge that we
are comparing similar groups of patients. The TNM system provides
information on the primary tumor's anatomical location and size and
on the presence of regional and distant metastases. Of course, this
information is useful in predicting survival. Considerable discrepancies
can occur between pretherapeutic classification and the actual exten-
sion of the tumor on pathologic analysis, particularly in the case of the
larger lesions. Despite recent advances in imaging techniques (CT and
MRI), the tumor's extension and especially its depth of invasion are
clinically very difficult to assess.
Increasing T class and stage was noted as a risk factor for recur-
rence in glottic LSCC in a Danish series with 5001 LSCC patients
treated with curative intent36 and also in the series of 1252 consecu-
tive LSCC patients by Johansen et al.7 Local extension of the primary
has an effect on treatment outcome. For example, in glottic tumors
the invasion of anterior commissure has been reported to increase the
risk of local failure of treatment.37,38
3.3 | N class
Treatment and prognosis for patients with laryngeal cancer are deter-
mined mainly by nodal status. The most significant single prognostic
indicator is the presence or absence of metastatic cancer in cervical
lymph nodes. This is supported both by the findings by Johansen
et al7 in a study of 1252 consecutive LSCC patients treated with
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primary RT and by Lyhne et al36 studying 5001 patients with glottic
LSCC in Denmark. Contralateral or bilateral nodal involvement is more
common in supraglottic primary tumors and portends a negative prog-
nosis. Although the number, size and level of invaded nodes is clearly
important, these factors are secondary to the overriding prognostic
significance of extracapsular spread.39 Errors in determining the pres-
ence and size of occult lymph node metastases have been reduced by
the use of ultrasound, ultrasound-guided fine-needle aspiration
biopsy, CT, MRI, and PET scans, all of which can improve the accuracy
of clinical staging in advanced disease. Use of the AJCC/UICC TNM
system provides prognostic information. In conclusion, the extent of
cervical lymph node metastatic distribution is clearly of paramount
prognostic importance.
3.4 | M class
Distant metastases in squamous cell carcinoma are usually preceded
by lymph node metastases. Blood-born metastases are uncommon,
but widespread dissemination to various viscera may occur in
advanced stages of laryngeal cancer. The sites which appear to be
most affected by distant metastatic spread are the mediastinal lymph
nodes, lungs, liver, pleura, skeletal system, kidney, heart, spleen, and
pancreas.40 The cavernous sinus and temporal bones are an unusual
site for metastasis. Naturally, distant metastases have been correlated
with a poor prognosis.
3.5 | Histological grading of malignancy
Approximately 90% of malignant neoplasms of the larynx are squa-
mous cell carcinomas and can be graded as well differentiated (G1),
moderately differentiated (G2), or poorly differentiated (G3). The
degree of a neoplasm's differentiation should not be confused with its
histological grading. Factors allowing for better assessment of the his-
tological grading of malignancies include1: degree of structural
differentiation,2 cellular anaplasia or pleomorphism,3 mitotic activity
index (frequency and abnormality of mitotic figures),4 expansive or
infiltrative growth,5 inflammatory response to the tumor,6 necrosis,
and7 lymphatic and blood vessel invasion.
Poorly differentiated cancers usually have a higher rate of meta-
static disease when compared with well-differentiated cancers, but
this correlation is not always valid.41 Also, the degree of differentia-
tion suffers from the subjectivity of interpretation by pathologists.
3.6 | Perineural invasion
The presence of perineural invasion (PNI), affecting small nerve is
associated with an increased risk of local recurrence and regional
nodal spread and has a negative impact upon the prognosis of patients
with laryngeal cancer.42
3.7 | Biological markers
There are now numerous emerging technologies that promise to pro-
vide much more prognostic information on neoplasms. Among the
developing technologies are: immunohistochemistry (immunohisto-
chemical detection of proliferation markers, such as the proliferating
cell nuclear antigen [PCNA] and Ki-67 [MIB 1]), molecular biology
analysis (p53, c-myc and ras, EGFR, and TGF-α), nucleolus organizer
regions (NORs), the determination of clonality by molecular diagnostic
techniques including the polymerase chain reaction (PCR), the use of
in situ hybridization (ISH), DNA ploidy by flow cytometry or image
analysis, TUNEL, cell cycle regulators (including p34cdc2 or CDK1,
and the D family of cyclins), among others.41 All present biological
parameters are often of “unproven” prognostic value. Considering the
current situation, it is impossible to define subgroups of patients with
a different biological behavior. Additional studies are needed to con-
firm these findings and compare the prognostic value of these and
other biomarkers with other parameters in large groups of patients,
with the support of sophisticated statistical analysis. Many papers
complete the discussion with an inconclusive remark, such as “this
marker could be of valid prognostic significance” but no acceptable
marker of prognosis has been identified thus far for clinical application
in patients with cancer of the larynx. The limitations of currently used
biological markers in predicting tumor behavior are well recognized in
laryngeal oncology. Conversely, there are many diagnostic markers
that are very useful to support the histologic diagnosis (such as neuro-
endocrine markers, etc.). However, having emphasized the need to
consider the prognostic implications of the new technologies with
caution, it is worth mentioning a few of the most promising reported
to date.
EGFR overexpression is established as a poor prognostic marker
in LSCC.43 However, no benefit regarding larynx preservation was
observed in a randomized trial by Bonner et al where cetuximab—a
monoclonal antibody targeting EGFR—was added to RT.44
The possibility to estimate LSCC radiosensitivity prior to treat-
ment remains an unsolved problem and there are no clinically applica-
ble means for this. WRAP53β has been suggested as a potential
biomarker for predicting RT/CRT response in T2-T3N0 glottic
LSCC.45
Recently, expression of sex hormone receptors, such as estrogen
receptor (ER-β) and progesterone receptor (PR), was studied by Atef
et al and was found significantly higher in poorly differentiated cases
and cases with lymphatic invasion while androgen receptor
(AR) expression was significantly lower in poorly differentiated cases
and with lymphatic invasion.46 The authors concluded, that ER-β and
PR may be considered as markers for poor behavioral pattern
in LSCC.
Molecular markers have been reported to have an important role
in detecting occult neoplastic cells in resection margins after head and
neck excision47 Genomic, transcriptomic, and protein alterations in
laryngeal cancer progression are key areas when aiming at investigation
of possible targets for classification and prognostication purposes.48
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PCR and cloning can identify a single malignant cell among 10 000 nor-
mal cells when the primary tumor contains a p53 mutation. Brennan
et al studied 25 patients with p53 mutation of their head and neck car-
cinomas and found one or more positive margins by means of this sen-
sitive molecular probe.49 These findings proved to be of great value in
a prognostic sense, in that the patients with negative margins by molec-
ular analysis were observed to have a significantly increased survival.
They also noted that there was a “lack of response to primary radiation
therapy in patients whose tumors harbor a p53 mutation” and
suggested that alternative and more aggressive therapy might be more
appropriate in this instance.
There has been considerable interest in the potential prognostic
value of the p5350,51 tumor suppressor gene and analyses of its gene
status (mutation) and protein status. In fact, the presence of high
levels of mutant p53 has clearly been associated with diminished sur-
vival.52 Nylander et al52 have also reported a significant association
between p53 expression and poor patient outcome specifically in
patients with laryngeal squamous cell carcinoma. The authors con-
clude that p53 could be one of several factors of importance in
predicting patient outcome.
Another potentially useful prognostic indicator is the bcl-2 gene.
It has been shown by immunohistochemical studies that bcl-2 gene
expression correlates significantly with poorly differentiated tumors
with the presence of nodal metastasis and with increased tumor
recurrence.53
When comparing the volume of high-quality scientific investiga-
tion concerning prognostic markers, we find a relative paucity of
reports in the field of laryngeal cancer relative to other more common
solid tumors (eg, lung, colon, and breast). Grénman et al reviewed the
published studies of markers in cancer of the larynx and concluded
that because of the complexity of cell-signaling phenomena, it is likely
that valuable prognostic tools will emerge from the measurement of
several factors in combination rather than from any one factor
alone.54
The UM-A9 monoclonal antibody will bind with most squamous
cell carcinoma cell culture lines, suggesting that it displays tumor spec-
ificity (as it will not bind to fibroblasts, lymphocytes, red blood cell,
melanomas, or normal keratinocytes). Immunohistology has confirmed
that most squamous cell carcinomas express this antigen and many
tumors show high levels of the antigen at the growing edge of tumor
nests and inside the tumor cells. Of the greatest importance in a prog-
nostic sense is the finding that the disease-free survival decreases in
head and neck squamous cell carcinoma patients as the intensity of
A9 antigen expression increases.55
Increased DNA content of laryngeal cancer cells as measured by
the adjusted DNA index (aDI) appears to reflect an increased prolifer-
ative capacity and a greater frequency of cervical lymph node metas-
tasis. Wolf et al studied 94 patients with stages III and IV laryngeal
carcinoma and found that a shorter time to recurrence, higher number
of positive nodes, and generally worse prognosis correlates with
higher levels of DNA content.56 Milroy et al believe that the role of
DNA ploidy as an independent prognostic indicator has yet to be
determined.57
In 2014, Bradford et al published a biomarker study in a prospec-
tive cohort of patients with advanced larynx cancer treated in a phase
II clinical trial.58 Important observations from this study included the
identification of tumor immunohistochemical expression of cyclin D as
a strong predictor of overall and disease-specific survival (P = .0008
and 0.0147, respectively). Further, the addition of cyclin D1 expression
added predictive information to a survival model using clinical stage
alone. In addition, tumors that overexpressed cyclin D1 were more
likely to have mutated p53. Moreover, aggressive histologic growth
pattern was associated with response to induction chemotherapy.
The incidence of p16INK4a/HPV positivity in LSCC is generally
low and the average of reported observations in the four meta-analyses
vary between 16% and 28%.59-62 Furthermore, there is a large geo-
graphical variation. The impact of p16INK4a in predicting treatment
outcome and survival in LSCC remains controversial, but it might have
a role in nonsmokers,63 females64 and younger LSCC patients.65
Clearly there is much work yet to be done to establish reliable,
independent biomarkers that predict survival and response to treat-
ment. The assessment of prognostic factors and biomarkers in
patients enrolled in prospective clinical trials is necessary to limit the
impact of uncontrolled variables that impact outcome and response.
3.8 | Second primary cancer
Another important factor influencing survival is the presence of other,
synchronous or metachronous primary cancers, whether in the head
and neck area or elsewhere, but especially in the esophagus, lung and
oral cavity. Cancers of the larynx tend to have second primaries in the
lung, whereas neoplasms in the oral cavity tend to have second pri-
maries in the esophagus. The presence of a previous or synchronous
cancer halves survival.66 Patients with cancer clearly are at a higher
risk of developing a second primary cancer.67
4 | TREATMENT FACTORS
An important factor in the management of cancer of the larynx is the
determination whether the carcinoma is in situ, microinvasive or
frankly invasive. “Minimal laryngeal cancer” defines carcinoma in situ
and microinvasive carcinoma, and the prognosis is generally favorable.
Invasive cancer of the larynx, left untreated, is inevitably a fatal dis-
ease: 90% of untreated patients die within 3 years.68 Treatment rec-
ommendations vary by tumor site and stage as well as patient factors.
Surgery and radiotherapy, either alone or in combination, are the con-
ventional modalities for the management of squamous cell carcinoma
of the larynx. Transoral laser microsurgery (TLM) and Transoral
Robotic Surgery (TORS) are alternatives to open surgery in specific
clinical scenarios at experienced head and neck centers. These trans-
oral approaches are most applicable in the treatment of early malig-
nant neoplasms of the supraglottic and glottic larynx. In squamous cell
carcinoma, chemotherapy in conjunction with radiotherapy is an alter-
native to laryngectomy in patients with advanced larynx cancer. The
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landmark VA Laryngeal Cancer Group Study, published in 1991, iden-
tified equivalent outcomes for patients with advanced larynx cancer
randomized to induction chemotherapy followed by radiation alone
for responders as compared to primary surgery (laryngectomy/neck
dissection) and postoperative adjuvant radiation.69 In 2003, Forastiere
et al published the results of the Radiation Therapy Oncology Group
91-11 follow-up study, that compared induction cisplatin/5-FU
(PF) followed by radiotherapy (RT), concomitant cisplatin/RT and RT
alone for patients with advanced larynx cancer.70 Patients with T4 pri-
maries were excluded from this trial. The 10-year follow-up results
were published in 2013 (Long-Term Results of RTOG 91-11).71 Impor-
tantly, overall survival did not differ in any of the treatment arms.
A recent paper published by Wolf et al72 suggested that superior
survival rates could be achieved with a bioselective treatment
approach that utilized a single cycle of neoadjuvant chemotherapy to
select subsequent treatment. Good survival rates were also achieved
in patients selected for primary surgery, and both neoadjuvant chemo-
therapy and primary surgery had better survival rates than with con-
current chemoradiotherapy. These data suggest that the optimal
individualized treatment approach for patients with advanced laryn-
geal cancer has not yet been defined, and likely does include surgery.
Chen et al utilized the National Cancer Database (NCDB) to
investigate clinical and demographic factors associated with improved
survival in patients with advanced laryngeal cancer diagnosed
between 1995 and 1998.73 They found that total laryngectomy
yielded the best survival in patients with advanced larynx cancer. The
authors did note that their results differed from the prospective ran-
domized clinical trial data, suggesting that caution is needed when
applying clinical trial findings to broader care settings. Lassig et al74
investigated the effect of treating institution (academic vs community)
on outcomes in head and neck cancer. Using Kaplan-Meier analysis,
they noted that the 5-year survival rate was 53.2% (95% confidence
interval [CI], 45.3%-61.1%) for academic centers and 32.8% (95% CI,
22%-43.6%) for community hospitals (P < 0.001). The paper by Gourin
et al provides support for the role of hospital volume as an important
factor in achieving optimal outcomes of therapy.75
Delays in diagnosis is an unfortunate phenomenon among LSCC
patients and this will obviously have an impact on tumor stage. Teppo
et al observed professional diagnostic delay (ie, the time from the first
doctor's appointment to the diagnosis) of 1 year or longer as an inde-
pendent predictor of local and regional failure.76
The treatment of laryngeal cancer should be selected according
to the best evidence with respect to site and stage of disease, patient
factors, the physician's experience, and treatment centers available.
Of course, the largest impact on the patient's quality of life is whether
or not the cancer is cured. However, treatment-related toxicities and
morbidity must be taken into account to optimize functional results.
5 | CONCLUSION
The TNM system is an anatomical means of classification, which takes
into account neither the biological aggressiveness of the specific
tumor nor the host's immunological response. It was not developed to
serve as a specific guideline for the management of a particular
patient, nor does the system have the ability to predict the outcome
of individual patients. Whereas physicians are focused on the concept
of optimal treatment, patients are interested in their prognosis, and
one of the most important tasks is to assess our present ability to pre-
dict the probable outcome for an individual patient with laryngeal
cancer.
The development and application of molecular biology tools to
analyze biopsy material may be predictive for the biological behavior
of laryngeal cancer but cannot be employed routinely at this time, but
significant progress is being made and biomarkers may inform both
prognosis and optimum treatment in the future.
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